Navigation Links
Crown Bioscience, Inc. Announces Closing of Series C Financing
Date:5/4/2011

ctors of dozens of different life sciences companies.

For more information, please visit: www.orbimed.com

About the CID Group

The CID Group was established in 1998, focusing on identifying and building top emerging Greater China companies.  The group manages over US$1 billion from top-tier strategic partners & investors as of 2010. There were 63 liquidity events out of 126 investments, including 39 IPOs and 24 M&As / trade sales as of 2009.

CID recruited and assembled a seasoned team with low turnover and more than 200 years of direct investment experiences.  Besides that, CID has established a dedicated research team as the engine to accumulate industry intelligence and further provide information asymmetry advantages.  Integrating Global Resources to Create Synergistic Businesses is group's mission, and CID aimed to leverage a unique and systematic investment strategy, and provide more value add to portfolio companies.  In line with the evolution of global technology migration and China's fast growing domestic markets, CID has outlined a clear and focused investment roadmap including semi-conductor, life science, wireless communication, FPD display, education, franchise and etc.

About Argonaut Private Equity

Argonaut Private Equity is a diversified global private equity fund dedicated to building emerging market leaders.  With more than $5.5 billion under management provided by a single entrepreneur, Argonaut exercises wide discretion on investment size, stage, sector and geography.  Because of its focused ownership and management, Argonaut can make quick decisions without fund restrictions on subsequent investments or exit timing.  Its equity investments range from $1 million to over $600 million and span such diverse markets as consumer electronics, energy, specialty materials, telecommunications, drug discovery
'/>"/>

SOURCE Crown Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
2. ULURU Inc. Announces the Filing of a 510(k) Application for Altrazeal® Collagen
3. Dehaier Medical Announces First Quarter 2011 Financial Results
4. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
5. Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results
6. Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management
7. HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Growth Stock Conference
9. Boston Scientific Announces CE Mark Approval and First Use of Blazer™ Open-Irrigated Catheter in Europe
10. Quest Diagnostics Announces One Day Extension of Offer to Acquire Celera to 5pm Today
11. Rigel Announces First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BOSTON , September 16, 2014 ... Fiona Marshall , will give a presentation entitled " ... StaR ®   technology " ... and Development " virtual symposium run by Chemical & Engineering ... symposium is on Wednesday, 24 September 2014; Dr Marshall,s presentation ...
(Date:9/15/2014)... Sept. 15, 2014 GenomeDx Biosciences today ... the American Society for Radiation Oncology (ASTRO) Annual ... Cancer Classifier, a genomic test capable of predicting ... and improve patient outcomes for prostate cancer patients ... a recently published study that demonstrates how Decipher ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- "Spain Aesthetic ... provides key market data on the Spain Aesthetic ... value, in millions of US dollars, volume (in ... market segments Invasive Body Contouring Devices (Laser-Assisted Liposuction ... Liposuction (RFAL) Devices, Ultrasound-Assisted Liposuction (UAL) Devices and ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 4Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 5
... Agent Ever to Demonstrate Significant Survival Benefit ... /PRNewswire-FirstCall/ -- Bayer,HealthCare Pharmaceuticals Inc. and Onyx ... significantly,extended overall survival in patients with hepatocellular ... taking placebo by 44%,(HR=0.69; p-value=0.0006). Results were ...
... WIRE)--Jun 4, 2007 - Researchers at,Molecular Insight ... on MIP-1072, a radiolabeled, small molecule,molecular imaging ... prostate cancer at the 54th annual meeting ... Washington, D.C. MIP-1072 is,one of two development ...
Cached Medicine Technology:Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 2Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 3Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 4Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 5Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 7Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 2Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 3Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 4
(Date:9/16/2014)... Terminsurancevirginia.com has released a new blog post ... insurance for obese clients. , Obese clients can ... It is unlikely for applicants to be denied coverage ... insurance costs. , Having life insurance is important ... insurance is available as temporary or permanent coverage and ...
(Date:9/16/2014)... Insuranceservicecompany.com has released a new blog ... investment tool. , Whole life insurance can provide financial ... used as an investment tool. Clients can save money for ... , A whole life insurance plan features a savings ... order for this policy to be profitable, clients should purchase ...
(Date:9/16/2014)... adage that warns against passing judgment based on ... species, apparently don,t share such human wisdom when ... University Polytechnic School of Engineering found that female ... fin color: yellow. The preference for yellow was ... , The reason may lie in the engineering-based, ...
(Date:9/16/2014)... According to a report by iData Research ( ... market research, the market for enteral feeding devices is ... U.S . and Europe combined. The market ... tubes, DPEJ tubes, PEG/J tubes. The enteral feeding replacement ... non-balloon tubes, nasogastric and nasojejunal tubes, enteral feeding pumps ...
(Date:9/16/2014)... 2014 Care Logistics® announced the ... of the Hospital Operating System™ that allows hospitals ... with staff capacity. For the first time, bed ... nursing and other staff capacity. , “The Demand ... anticipated admissions, discharges and transfers, real staff capacity ...
Breaking Medicine News(10 mins):Health News:Obese Clients Can Find Affordable No Exam Term Life Insurance at Terminsurancevirginia.com! 2Health News:Whole Life Insurance Can Be A Good Investment Tool for Retirement! 2Health News:Judging a fish by its color: for female bluefin killifish, love is a yellow mate 2Health News:Judging a fish by its color: for female bluefin killifish, love is a yellow mate 3Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 2Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 3Health News:Care Logistics Launches Demand Logistics as Part of the Hospital Operating System 2
... ) launches the GlaceComplete product suite which seamlessly integrates EMR ... billing process. The product has been designed to reduce the ... for the average office based medical practice. , ... ...
... piezoelectric transducers in industrial applications, and to facilitate transducer evaluation in ... ... 26, 2009 -- Piezoelectric elements have a myriad of uses. They ... in a structure. They can be used to acoustically cancel noise, ...
... that is responsible for maintaining the health of the light-sensing ... retina for the first time. , The ability to see ... of many diseases of the eye long before a patient ... Investigative Ophthalmology and Visual Science ., "Our goal is to ...
... Feb. 25 PharmaNet Development Group, Inc. (the "Company") ... clinical development services, today reported preliminary net income for ... million, or $0.08 per diluted share, compared to net ... per diluted share, in the fourth quarter 2007. All ...
... for February 26, 2009 at 10:00 a.m. EST , EAST ... SVNT ) today reported financial results for the three months and ... 2008, the Company had a net loss of $24.2 million, or ... the year ended December 31, 2008, the Company had a net ...
... with record bookings and continued positive cash flow ... AMCS ), a leader in radiology ... reported unaudited financial results for the fourth quarter ... http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ) Q4 Financial Highlights Revenue ...
Cached Medicine News:Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 3Health News:Amped Up Piezos Are On The Move - Driving Piezos with an Affordable High Voltage Piezo Amplifier QPA200 2Health News:Amped Up Piezos Are On The Move - Driving Piezos with an Affordable High Voltage Piezo Amplifier QPA200 3Health News:'Dark cells' of living retina imaged for the first time 2Health News:'Dark cells' of living retina imaged for the first time 3Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 2Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 3Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 4Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 5Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 6Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 7Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 8Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 9Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 10Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 11Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 12Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 13Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 14Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 15Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 16Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 17Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 2Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 3Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 4Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 5Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 6Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 7Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 8Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 9Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 3Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 4Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 5Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 6
... This new kit uses proteins produced with ... Latin America, and which are capable of detecting ... this area. They are proteins with amino acid ... antigen) antigen. During the acute phase of the ...
The Cellabs T. cruzi IgG CELISA is a direct ELISA kit designed to detect antibodies produced during T. cruzi infections (Chagas disease)....
... The Cypress quick test is a ... of antibodies to Trypanosoma cruzi. It ... or plasma. The method employs a unique ... which is conjugated on dye particles, and ...
... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
Medicine Products: